等待开盘 11-07 09:30:00 美东时间
0.000
0.00%
Autolus Therapeutics plc will release its third quarter 2025 financial results and operational highlights before U.S. markets open on November 12, 2025. Senior management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the results and provide a business update. Participants must pre-register via a provided link to receive dial-in details and a PIN. A live audio webcast and replay will be available on the company’s we...
10-30 11:00
Coherent Corp. announces the launch of its next generation polarization-maintai...
10-29 04:05
The Company's 25th location in the state is now accepting patients. BIRMINGHAM, Ala. and ST. PETERSBURG, Fla., Oct. 21, 2025 /PRNewswire/ -- Today, Encompass Health, the nation's largest own...
10-22 04:30
Executive Chairman Mark T. Mondello and Directors Kathleen A. Walters and Jamie Siminoff to Depart the Board; Lead Director Steve Raymund Expected to Become ChairmanST. PETERSBURG, Fla.--(BUSINESS WIRE)-- Jabil Inc.
10-17 04:32
CANONSBURG, Pa., Oct. 8, 2025 /PRNewswire/ -- Today, Core Natural Resources, Inc. (NYSE: CNR) ("Core," the "company," "we" or "our") announced that its board of directors has appointed Core'...
10-08 19:55
Synchrony Acquired Versatile Credit's Multi-Source Financing Platform, Expanding Technological Capabilities Versatile Credit Will Continue Serving Many Lenders And Merchants STAMFORD, Conn. ...
10-02 04:45
Frey Creek and Riverdale Hills are anticipated to open this fall, with new homes starting from the mid $200s SPARTANBURG, S.C., Oct. 1, 2025 /PRNewswire/ -- Century Communities, Inc. (NYSE: ...
10-02 00:38
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's
09-30 21:08
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matri...
09-30 21:01
- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -- Company to provide update at the H.C. Wainwright 27th Annual
09-09 20:38